Overview

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zenith Epigenetics